Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Refractory/Relapse Neuroblastoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroendocrine Tumors 1Neoplasms, Squamous Cell 1Neoplasms 1Nasopharyngeal Carcinoma 1Lymphoma 1Lung Neoplasms 1Hysterectomies for Low- or Intermediate-risk Endometrial Carcinoma 1Esophageal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Cyclophosphamide 104fludarabine 61Methotrexate 50Dexamethasone 47Cytarabine 46fludarabine phosphate 45Vincristine 43blinatumomab 36Whole-Body Irradiation 33Mycophenolic Acid 30Tacrolimus 26Melphalan 26Mercaptopurine 25venetoclax 24Specimen Handling 24Etoposide 24pegaspargase 21Peripheral Blood Stem Cell Transplantation 21Stem Cell Transplantation 20Granulocyte Colony-Stimulating Factor 19Doxorubicin 19Calcium Dobesilate 19Busulfan 19Rituximab 16Prednisone 16Filgrastim 16Daunorubicin 16Asparaginase 16merphos 15Thiotepa 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × Biological Products × 1 year × Clear all
NCT01430390 2025-06-11

In Vitro Expanded Allogeneic Epstein-Barr Virus Specific Cytotoxic T-Lymphocytes (EBV-CTLs) Genetically Targeted to the CD19 Antigen in B-cell Malignancies

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
19 enrolled
LymphoidOther hematologic neoplasm

Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡